PL3139948T3 - Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 - Google Patents

Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21

Info

Publication number
PL3139948T3
PL3139948T3 PL15720982T PL15720982T PL3139948T3 PL 3139948 T3 PL3139948 T3 PL 3139948T3 PL 15720982 T PL15720982 T PL 15720982T PL 15720982 T PL15720982 T PL 15720982T PL 3139948 T3 PL3139948 T3 PL 3139948T3
Authority
PL
Poland
Prior art keywords
glp
treatment
diabetes type
diabetes
type
Prior art date
Application number
PL15720982T
Other languages
English (en)
Inventor
Ken COPPIETERS
Matthias Von Herrath
Tamar BOURSALIAN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3139948T3 publication Critical patent/PL3139948T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15720982T 2014-05-07 2015-05-05 Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 PL3139948T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989841P 2014-05-07 2014-05-07
EP14169596 2014-05-23
EP14189732 2014-10-21
EP15720982.6A EP3139948B1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21
PCT/EP2015/059811 WO2015169789A1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21

Publications (1)

Publication Number Publication Date
PL3139948T3 true PL3139948T3 (pl) 2020-08-10

Family

ID=54392180

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15720982T PL3139948T3 (pl) 2014-05-07 2015-05-05 Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21

Country Status (9)

Country Link
US (1) US10105442B2 (pl)
EP (1) EP3139948B1 (pl)
JP (1) JP6672175B2 (pl)
CN (1) CN106999553B (pl)
PL (1) PL3139948T3 (pl)
RS (1) RS60316B1 (pl)
SI (1) SI3139948T1 (pl)
TW (1) TWI668010B (pl)
WO (1) WO2015169789A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017149109A1 (en) * 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in diabetic foot ulcer
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2025257327A1 (en) 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP3254687A1 (en) 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
WO2003105897A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
WO2005056036A2 (en) * 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
WO2006074051A2 (en) 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
MX2008001468A (es) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
CA2658678A1 (en) 2005-08-06 2007-02-15 Gerald J. Prud'homme Composition and method for prevention and treatment of type i diabetes
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
PL2347762T3 (pl) * 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
MEP8509A (en) * 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
CA2689895A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
CN105727261A (zh) * 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
JP5832439B2 (ja) * 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20130071860A1 (en) 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`
US20130323259A1 (en) * 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
WO2012150319A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
US20140178395A1 (en) 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of nephropathy

Also Published As

Publication number Publication date
RS60316B1 (sr) 2020-07-31
US20170043014A1 (en) 2017-02-16
SI3139948T1 (sl) 2020-07-31
JP6672175B2 (ja) 2020-03-25
CN106999553A (zh) 2017-08-01
TW201625289A (zh) 2016-07-16
EP3139948A1 (en) 2017-03-15
CN106999553B (zh) 2021-11-26
JP2017514860A (ja) 2017-06-08
WO2015169789A1 (en) 2015-11-12
US10105442B2 (en) 2018-10-23
TWI668010B (zh) 2019-08-11
EP3139948B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
PL3105213T3 (pl) Związki dihydrobenzofuranu użyteczne w leczeniu cukrzycy i otyłości
GB201403093D0 (en) Therapeutic compounds and their use
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
ZA201806637B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
IL246757A0 (en) New insulin histories and their medical uses
PT3297653T (pt) Tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
ZA201608281B (en) Ppar compounds for use in the treatment of fibrotic diseases.
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
IL258511B (en) Compounds and their medicinal uses
IL254496B (en) Treatment of type 2 diabetes patients
GB201707207D0 (en) Treatment of type 1 diabetes
IL252899A0 (en) Cross-linked polydiallyamine copolymers for the treatment of type 2 diabetes
IL254500A0 (en) Treatment of patients with type 2 diabetes
SI3139948T1 (sl) Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
IL250666A0 (en) A peptide for the treatment of diabetes mellitus type 2 and its complications
GB201513543D0 (en) Compositions for use in the treatment of diabetes
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201418541D0 (en) Materials for use with general hyperthermia treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
GB201417777D0 (en) Novel compounds and therapeutic uses thereof
ZA201404780B (en) Composition for use in treatment of diabetes
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use